Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis

Masahiro Tada; Takeshi Nakanishi; Chika Hirata; Tadashi Okano; Yuko Sugioka; Shigeyuki Wakitani; Hiroaki Nakamura; Tatsuya Koike

doi:10.1007/s10165-010-0336-0

Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis

Mod Rheumatol. 2010 Dec;20(6):598-601. doi: 10.1007/s10165-010-0336-0. Epub 2010 Aug 4.

Authors

Masahiro Tada¹, Takeshi Nakanishi, Chika Hirata, Tadashi Okano, Yuko Sugioka, Shigeyuki Wakitani, Hiroaki Nakamura, Tatsuya Koike

Affiliation

¹ Department of Orthopaedic Surgery, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.

PMID: 20680379
DOI: 10.1007/s10165-010-0336-0

Abstract

Pyoderma gangrenosum (PG) is characterized by ulcerative skin lesions. Infliximab (IFX) may promote PG healing in patients with inflammatory bowel disease, but whether IFX is effective for treating PG in patients with rheumatoid arthritis (RA) has not reported. We report the case of a 53-year-old woman with PG complicated by RA who was treated using IFX therapy. This case suggests that IFX therapy might offer effective treatment for such patients.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / complications
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / pathology
Female
Humans
Infliximab
Middle Aged
Pyoderma Gangrenosum / complications
Pyoderma Gangrenosum / drug therapy*
Pyoderma Gangrenosum / pathology
Skin / drug effects
Skin / pathology
Treatment Outcome

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Infliximab